Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp > Zenith Announces Clinical Collaboration with Astellas

<< Previous

Bullboard Posts

Next >>

Comment by G1945Von Apr 26, 2021 9:57am

210 Views

Post# 33065883

RE:RE:Zenith Announces Clinical Collaboration with Astellas

jk.... based on their Jan 31, 2021, financials their cash position; $186K. US
The amount owing to RVX; $621K. US
They gained approx $2.4Mil US exempt distribution since Jan 31, 2021.
Perhaps they can afford to pay RVX the amount owing; $621K US

G1945V

<< Previous

Bullboard Posts

Next >>

Rich TV Live's Stocks to Watch this week (Nov. 22, 2024)